Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | GMNN | O75496 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27469410 | 0.98 | LMNA (0.60) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| Zinc Ion SCHEMBL7620932 | 0.97 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL27669980 | 0.97 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL3899729 | 0.97 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL27768779 | 0.93 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL27925466 | 0.93 | LMNA (0.66) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL27493791 | 0.92 | LMNA (0.64) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL94476 | 0.87 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL93717 | 0.87 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL2163300 | 0.87 | LMNA (0.58) | LMNASMN1; SMN2CYP1A2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245537-A1 | L-carnitine calcium fumarate, preparation method and application for the same | Liaoning Konepnutra Co., Ltd | 2011-10-06 | — | — | US | disclosed |
| EP-2125700-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | Shenyang Koncepnutra Corporation, Limited (CN) | 2009-12-02 | — | — | EP | disclosed |
| US-20090281183-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2009-11-12 | — | — | US | disclosed |
| WO-2008080287-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SHENYANG KONCEPNUTRA CORPORATION, LIMITED (CN) | 2008-07-10 | — | — | WO | disclosed |
| CN-1219748-C | Solid compositions suitable for oral administration containing non-hydroscopic salts of L-carnitine and alkanoyl L-carnitines with taurine chloride and glycine chloride | SIGMA TAU IND FARMACEUTI (IT) | 2005-09-21 | — | — | CN | disclosed |
| CN-1473144-A | Solid compositions suitable for oral administration containing non-hygroscopic salts of L-carnitine and alkanoyl L-carnitines with taurine chloride and glycine chloride | ϣ��������ҩ��ҵ��˾ | 2004-02-04 | — | — | CN | disclosed |
| WO-2002059075-A1 | SALTS OF CARNITINES USEFUL AS DIETARY/NUTRITIONAL SUPPLEMENTS OR DRUGS, PROCESSES FOR PREPARING SAME AND COMPOSITIONS CONTAINING SUCH SALTS | FASSI, ALDO (IT) | 2002-08-01 | — | — | WO | disclosed |
| US-6130249-A | Solid compositions suitable for oral administration comprising L-carnitine and alkanoyl-L-carnitine magnesium tartrate | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281183-A1 | L-CARNITINE CALCIUM FUMARATE, PREPARATION METHOD AND APPLICATION FOR THE SAME | SLC25A20, FH, CA2 | LMNA 679/4885SMN1; SMN2 685/4885CYP1A2 3035/4885 |
| US-20110245537-A1 | L-carnitine calcium fumarate, preparation method and application for the same | SLC25A20, FH, CA2 | LMNA 681/4885SMN1; SMN2 691/4885CYP1A2 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.